Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis
Philosophical Transactions of the Royal Society B: Biological Sciences · 2026
DOI: 10.1098/rstb.2024.0512 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Philosophical Transactions of the Royal Society B: Biological Sciences, 2026. Verfasst von Arturo Simoni-Nieves und 3 weiteren Autor:innen. Beteiligte Einrichtung: Avenida San Rafael Atlixco No. 186, Colinas de Leyes de Reforma/Col. Vicentina, Alcaldía Iztapalapa , C.P. 09310/09340, Ciudad de México. Hauptthemen laut MEDLINE: ErbB Receptors, Signal Transduction, Lung Neoplasms, Mutagenesis. Die Arbeit nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation, European Research Council (ERC), Israel Cancer Research Fund (ICRF).
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) plays pivotal role in cancer promotion and progression, particularly in non-small cell lung cancer (NSCLC), where activating EGFR mutations drive tumour growth. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have improved patient survival rates, but resistance inevitably develops through mechanisms ranging from secondary mutations to bypass signalling pathways and histological transformation. A key factor in resistance development is the emergence of drug-tolerant persister cells, a rare population with epigenetic alterations that precede permanent, mutation-driven resistance. These cells evade apoptosis by triggering an evolutionarily conserved survival mechanism known as SOS. The SOS process is accompanied by increased reactive oxygen species, DNA breaks, defective DNA repair and activation of mutation-inducing factors like error-prone DNA polymerases and imbalanced dNTP pools. In patients receiving TKIs, this adaptive response probably drives the formation of extrachromosomal circular DNA and various genomic aberrations, collectively resembling chromothripsis. The aberrations include not only point mutations and gene amplifications but also indels and gene fusions. To overcome resistance, new therapeutic strategies are being explored, such as fourth-generation TKIs, allosteric inhibitors, degraders and bispecific antibodies. Ongoing research into EGFR biology offers the potential to transform EGFR-positive NSCLC from a lethal disease into a chronic, manageable condition. This article is part of the discussion meeting issue ‘Epidermal growth factor receptor after 40 years’.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Avenida San Rafael Atlixco No. 186, Colinas de Leyes de Reforma/Col. Vicentina, Alcaldía Iztapalapa , C.P. 09310/09340, Ciudad de México.
- Weizmann Institute of Science , 234 Herzzl Street, Rehovot 7610001, Israel.
- 8730 Twin Lake Drive, Boca Raton , FL 33496, USA.
Förderung
- Israel Science Foundation
- European Research Council (ERC)
- Israel Cancer Research Fund (ICRF)
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Zitieren
APA
Simoni-Nieves, A., Van Daele, M., Konsker, H. B., & Yarden, Y. (2026). Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis. Philosophical Transactions of the Royal Society B: Biological Sciences. https://doi.org/10.1098/rstb.2024.0512
Vancouver
Simoni-Nieves A, Van Daele M, Konsker HB, Yarden Y. Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis. Philosophical Transactions of the Royal Society B: Biological Sciences. 2026. doi:10.1098/rstb.2024.0512
BibTeX
@article{SimoniNieves2026,
author = {Simoni-Nieves, Arturo and Van Daele, Marieke and Konsker, Harrison B and Yarden, Yosef},
title = {Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis},
journal = {Philosophical Transactions of the Royal Society B: Biological Sciences},
year = {2026},
doi = {10.1098/rstb.2024.0512}
}
EUVIMED